Enanta Pharmaceuticals | ENTA - Net Income


Enanta Pharmaceuticals reported $-22.29M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Amgen USD 1.82B 486M Mar/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -132.73M 163.54M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Biogen USD 319.5M 368.4M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Incyte USD 303.33M 4.05M Mar/2026
Insmed USD -163.56M 164.92M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
J&J USD 5.24B 119M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Ligand Pharmaceuticals USD -13.34M 58.13M Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD 2.69B 4.34B Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026